Lila Sciences has raised $235 million in a Series A financing round to scale its AI-driven scientific research platform that integrates generative AI, robotics, and automated lab systems. The company’s mission is to dramatically accelerate and enhance drug discovery processes, aiming to create transformative therapeutics with higher intelligence, scale, and speed. The latest funding will support talent acquisition in multiple scientific disciplines and expand operational and geographic presence including Cambridge, San Francisco, and London.